Evidence map›Paper›PMID 40801833›Full record

ArticleAntimicrobial agents and chemotherapy2025

Amoxicillin vs. ceftriaxone to treat pneumonia caused by amoxicillin-non-susceptible

Daniel M Musher

Abstract readComment
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Daniel M MusherDepartment of Medicine, Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0002-7571-066X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the article by J Càmara, I Grau, A González-Díaz, N Santos, et al. (Antimicrob Agents Chemother 69:e00237-25, 2025, https://doi.org/10.1128/aac.00237-25) suggests that ceftriaxone is greatly superior to amoxicillin in treating pneumonia due to pneumococci with an MIC > 2 mg/L, much of the difference in efficacy of the two drugs may have been due to dosage, route, and times of administration of the amoxicillin.

Indexed as

AmoxicillinAnti-Bacterial AgentsCeftriaxonePneumonia, PneumococcalStreptococcus pneumoniaeHumansMicrobial Sensitivity TestsAmoxicillinAnti-Bacterial AgentsCeftriaxoneamoxicillinceftriaxonepneumoniaStreptococcus pneumoniae

Identifiers

PMID40801833
PMCPMC12406684

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.